ReviewPaediatric drugs2026
Established and Emerging Therapies for High-Risk Neuroblastoma.
Review in Paediatric drugs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Eflornithine for neuroblastoma.Australian prescriber · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
High-risk neuroblastoma (HRNB) accounts for a disproportionately high percentage of cancer-related deaths among pediatric patients, despite intensive multimodal treatment. Current frontline therapy comprising chemotherapy, surgery, autologous stem cell transplantation (ASCT), radiation, immunotherapy, and tumor differentiation agents has improved survival rates; however, overall outcomes have plateaued. Refractory and relapsed cases are associated with even poorer prognoses, underscoring the limitations of existing treatment regimens. Additionally, treatment-related toxicities from intensive therapies pose significant risks to patients' quality of life and long-term health, highlighting the need for novel therapeutic approaches. In response, recent efforts have focused on integrating new modalities into frontline therapy, such as anti-GD2 immunotherapy, iodine-131 (
Indexed as
Identifiers
41746475What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.